Table 3

Association between Anti-Ro52/TRIM21 antibodies and disease severity (range, 0 to 4)

Whole group

(N = 963)

Anti-Ro52/TRIM21 antibody positive (n = 194)

Anti-Ro52/TRIM21 antibody negative (n = 769)

Odds ratio (95% CI) and P values (Anti-Ro52/TRIM21 positive vs negative)


Mean

SD

Mean

SD

Mean

SD


General

0.89

1.22

1.16

1.41

0.82

1.16

1.23 (1.09, 1.39)

0.0061

Skin

1.25

0.68

1.23

0.60

1.25

0.69

NS

Kidney

0.12

0.61

0.12

0.61

0.12

0.61

NS

Peripheral vascular

1.54

1.25

1.58

1.26

1.53

1.24

NS

Joint/tendon

0.73

1.19

0.73

1.22

0.73

1.18

NS

Muscle

0.25

0.74

0.33

0.89

0.22

0.70

NS

Gastrointestinal

1.95

0.82

2.01

0.78

1.93

0.82

NS

Lung

1.38

1.11

1.56

1.08

1.34

1.12

1.19 (1.04, 1.37)

0.0084

Heart

0.50

1.00

0.60

1.12

0.48

0.97

NS

Physician global assessments of severity (range, 0-10)

2.77

2.26

2.99

2.31

2.71

2.24

NS

Patient global assessments of severity (range, 0-10)

3.64

2.61

3.66

2.67

3.63

2.60

NS


CI, confidence interval; NS, not significant; SD, standard deviation.

Hudson et al. Arthritis Research & Therapy 2012 14:R50   doi:10.1186/ar3763

Open Data